Inhibikase Tangible Book Value Per Share from 2010 to 2024

IKT Stock  USD 2.73  0.37  15.68%   
Inhibikase Therapeutics Tangible Book Value Per Share yearly trend continues to be comparatively stable with very little volatility. Tangible Book Value Per Share will likely drop to 2.05 in 2024. From the period from 2010 to 2024, Inhibikase Therapeutics Tangible Book Value Per Share quarterly data regression had r-value of  0.57 and coefficient of variation of  369.33. View All Fundamentals
 
Tangible Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
2.05845198
Current Value
2.05
Quarterly Volatility
4.01385662
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inhibikase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibikase Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.9 K, Net Interest Income of 935.8 K or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 24.7, Dividend Yield of 0.0 or PTB Ratio of 0.65. Inhibikase financial statements analysis is a perfect complement when working with Inhibikase Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Inhibikase Therapeutics Correlation against competitors.
For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

Latest Inhibikase Therapeutics' Tangible Book Value Per Share Growth Pattern

Below is the plot of the Tangible Book Value Per Share of Inhibikase Therapeutics over the last few years. It is Inhibikase Therapeutics' Tangible Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibikase Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Tangible Book Value Per Share10 Years Trend
Slightly volatile
   Tangible Book Value Per Share   
       Timeline  

Inhibikase Tangible Book Value Per Share Regression Statistics

Arithmetic Mean1.09
Geometric Mean1.69
Coefficient Of Variation369.33
Mean Deviation2.96
Median(1.04)
Standard Deviation4.01
Sample Variance16.11
Range15.2683
R-Value0.57
Mean Square Error11.72
R-Squared0.32
Significance0.03
Slope0.51
Total Sum of Squares225.55

Inhibikase Tangible Book Value Per Share History

2024 2.05
2023 2.06
2022 5.01
2021 12.66
2020 5.84
2019 -2.61
2018 -0.58

About Inhibikase Therapeutics Financial Statements

Inhibikase Therapeutics shareholders use historical fundamental indicators, such as Tangible Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Inhibikase Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Inhibikase Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Inhibikase Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Tangible Book Value Per Share 2.06  2.05 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.